


I'm not a bot













(10); 1028-40. doi:10.1056/NEJMra044440. PMID 16148288. ^ "Exanta". Ask Dr. Stephan Moll. The Thrombophilia Awareness Project. Archived from the original on 2006-03-18. ^ Manfredi M, Dave B, Percudani D, Christoforou J, Karasneh J, Diz Dios P, et al. (June 2019). "World workshop on oral medicine VII: Direct anticoagulant agents management for invasive oral procedures: A systematic review and meta-analysis". *Oral Diseases*. 25 (S1): 157-73. doi:10.1111/odi.13086. PMID 31140701. S2CID 169034257. ^ Bensli C, Belli S, Paradiso D, Lomurno G (July 2018). "Postoperative bleeding risk of direct oral anticoagulants after oral surgery procedures: a systematic review and meta-analysis". *International Journal of Oral and Maxillofacial Surgery*. 47 (7): 923-32. doi:10.1016/j.ijom.2018.03.016. PMID 29627150. S2CID 4697607. ^ Costantinides F, Rizzo R, Pascasio L, Maglione M (January 2016). "Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications". *BMC Oral Health*. 16: 5. doi:10.1186/s12903-016-0170-7. PMC 4731944. PMID 26822674. ^ Kosyfaki P, Att W, Strub JR (August 2011). "The dental patient on oral anticoagulant medication: a literature review". *Journal of Oral Rehabilitation*. 38 (8): 615-33. doi:10.1111/j.1365-2842.2010.02184.x. PMID 21073495. ^ van Diermen DE, van der Waal I, Hoogstraten J (December 2013). "Management recommendations for invasive dental treatment in patients using oral antithrombotic medication, including novel oral anticoagulants". *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*. 116 (6): 709-16. doi:10.1016/j.oooo.2013.07.026. PMID 24120910. ^ Shi Q, Xu J, Zhang T, Zhang B, Liu H (2017-02-08). "Post-operative Bleeding Risk in Dental Surgery for Patients on Oral Anticoagulant Therapy: A Meta-analysis of Observational Studies". *Frontiers in Pharmacology*. 8: 58. doi:10.3389/fphar.2017.00058. PMC 5296357. PMID 28228727. ^ "Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs: Dental Clinical Guidance" (PDF). Scottish Dental Clinical Effectiveness Programme. Archived from the original (PDF) on 2017-03-28. Retrieved 2020-01-09. ^ a b "Thrombate III label" (PDF). Archived from the original (PDF) on 2012-11-15. ^ Center for Biologics Evaluation and Research (24 April 2019). "Fractionated Plasma Products - ATryn". *www.fda.gov*. ^ a b "Antithrombin (Recombinant) US Package Insert ATryn for Injection February 3, 2009" (PDF). Food and Drug Administration. ^ a b Tornkvist M, Smith JG, Labaf A (February 2018). "Current evidence of oral anticoagulant reversal: A systematic review". *Thrombosis Research*. 162: 22-31. doi:10.1016/j.thromres.2017.12.003. PMID 29258056. ^ Hanley JP (2004-11-01). "Warfarin reversal". *Journal of Clinical Pathology*. 57 (11): 1132-39. doi:10.1136/jcp.2003.008904. ISSN 0021-9746. PMC 1770479. PMID 15509671. ^ Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF (March 1997). "Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy". *Thrombosis and Haemostasis*. 77 (3): 477-80. doi:10.1055/s-0038-1655992. ISSN 0340-6245. PMID 9065997. S2CID 45458169. ^ Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, et al. (September 2016). "Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis". *Thrombosis and Haemostasis*. 116 (11): 879-90. doi:10.1160/TH16-04-0266. ISSN 0340-6245. PMID 27488143. S2CID 4733615. ^ Pakraftar S (2014). "Dabigatran etixilate and traumatic brain injury: Evolving anticoagulants require evolving care plans". *World Journal of Clinical Cases*. 2 (8): 362-66. doi:10.12998/wjcc.v2.i8.362. ISSN 2307-8960. PMC 4133427. PMID 25133148. ^ Ryn Jv, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. (2010). "Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity". *Thrombosis and Haemostasis*. 103 (6): 1116-27. doi:10.1160/TH09-11-0758. ISSN 0340-6245. PMID 20352166. S2CID 37404563. ^ Siegal DM, Curmutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. (2015-12-17). "Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity". *New England Journal of Medicine*. 373 (25): 2413-24. doi:10.1056/NEJMoa1510991. ISSN 0028-4793. PMID 26559317. ^ Connolly SJ, Milling TJ, Eikelboom JW, Gibson CM, Curmutte JT, Gold A, et al. (2016-09-22). "Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors". *New England Journal of Medicine*. 375 (12): 1131-41. doi:10.1056/NEJMoa1607887. ISSN 0028-4793. PMC 5568772. PMID 27573206. ^ Reed M, Tadi P, Nicolas D (2020), "Andexanet Alfa", StatPearls, StatPearls Publishing, PMID 30137783, retrieved 2020-01-23 ^ Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso MA, Brown K, et al. (February 2017). "Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban". *Thrombosis and Haemostasis*. 117 (2): 238-45. doi:10.1160/TH16-03-0224. ISSN 0340-6245. PMC 6260118. PMID 27853809. ^ Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011-10-04). "Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects". *Circulation*. 124 (14): 1573-79. doi:10.1161/CIRCULATIONAHA.111.029017. ISSN 0009-7332. PMID 21900088. S2CID 961167. ^ Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski J, Pernod G (2012). "Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: A randomised crossover ex vivo study in healthy volunteers". *Thrombosis and Haemostasis*. 108 (8): 217-24. doi:10.1160/TH12-03-0179. ISSN 0340-6245. PMID 22627883. S2CID 28694620. ^ "Bethesda unit". Biology Online. Retrieved 2009-02-14. ^ Schumacher HR (2000). *Handbook of Hematologic Pathology*. Informa Health Care. p. 583. ISBN 978-0-8247-0170-3. ^ Norman M, Jones I (May 2014). "The shift from fluoride/oxalate to acid citrate/fluoride blood collection tubes for glucose testing - The impact upon patient results". *Clinical Biochemistry*. 47 (7-8): 683-85. doi:10.1016/j.clinbiochem.2014.01.011. PMID 24463230. ^ "Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs - New guidance from SDCEP | Scottish Dental". 15 September 2015. Retrieved 2020-02-20. ^ Fredenburgh JC, Weitz JI (12 October 2020). "New Anticoagulants: Moving Beyond the Direct Oral Anticoagulants". *Journal of Thrombosis and Haemostasis*. 19 (1): 20-29. doi:10.1111/jth.15126. PMID 33047462. S2CID 222320654. ^ Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, et al. (November 2021). "Milvexian for the Prevention of Venous Thromboembolism". *The New England Journal of Medicine*. 385 (23): 2161-72. doi:10.1056/NEJMoa2113194. PMC 9540352. PMID 34780683. S2CID 244132392. ^ Wong PJ, Mosley SA, Ng TM, Shoostari A, Alexander GC, Qato DM (2022-12-26). "Changes in anticoagulant and antiplatelet drug supply at US hospitals before and during the COVID-19 pandemic (2018-2021)". *American Journal of Health-System Pharmacy*. 80 (11): 692-98. doi:10.1093/ajhp/zxac381. ISSN 1079-2082. ^ Lee E, Bates B, Kuhn N, Andersen KM, Visaria A, Patel R, et al. (2023-10-03). "National Trends in Anticoagulation Therapy for COVID-19 Hospitalized Adults in the United States: Analyses of the National COVID Cohort Collaborative". *The Journal of Infectious Diseases*. 228 (7): 895-906. doi:10.1093/infdis/jiad194. ISSN 0022-1899. PMC 10547450.{{cite journal}}: CS1 maint: numeric names: authors list (link) Staying Active and Healthy with Blood Thinners by the Agency for Healthcare Research and Quality Retrieved from "